Home
About
Overview
Sharing Data
ORCID
Help
History (1)
Response as a predictor of survival in patients with recurrent glioblastoma treated with bevacizumab.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Response as a predictor of survival in patients with recurrent glioblastoma treated with bevacizumab.
Response as a predictor of survival in patients with recurrent glioblastoma treated with bevacizumab. Neuro Oncol. 2011 Jan; 13(1):143-51.
View in:
PubMed
subject areas
Aged
Angiogenesis Inhibitors
Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Bevacizumab
Brain Neoplasms
Female
Glioblastoma
Humans
Male
Neoplasm Recurrence, Local
Salvage Therapy
Survival Rate
Treatment Outcome
Vascular Endothelial Growth Factor A
authors with profiles
Martin Nicholas
Nina Paleologos